Physician profile
Edward Chen
NPI 1982133633
$20,106.28
in general payments reported to CMS, 2019-2025
32 companies · $8,829 in 2025
The $8,829 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $1,924 · 2021: $586 · 2022: $2,138 · 2023: $2,300 · 2024: $3,760 · 2025: $8,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,385 · Consulting Fee: $5,825 · Education: $493 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,385.04 |
| Consulting Fee | $5,825.00 |
| Education | $493.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,389.95 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,583.25 | 2020-2025 | Sotyktu |
| Janssen Biotech, INC. | $2,299.97 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,979.29 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,356.28 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $891.77 | 2021-2025 | |
| Incyte Corporation | $633.98 | 2021-2025 | Opzelura |
| Ucb, INC. | $613.39 | 2022-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $475.53 | 2021-2025 | Ilumya |
| Amgen INC. | $468.09 | 2021-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $443.74 | 2020-2025 | Ebglyss, Olumiant, Taltz |
| Mayne Pharma Commercial LLC | $338.67 | 2022-2025 | |
| Leo Pharma INC. | $338.15 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $333.48 | 2022-2025 | Nemluvio |
| Genzyme Corporation | $299.48 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $250.93 | 2021-2024 | Seysara, Klisyri |
| Kerecis Limited | $241.26 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Dermavant Sciences, INC. | $221.53 | 2022-2024 | Vtama |
| Allergan, INC. | $136.36 | 2022 | |
| Dermira, INC. | $125.00 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $121.86 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.70 | 2019-2024 | Jublia |
| Arcutis Biotherapeutics, INC. | $73.84 | 2023-2025 | Zoryve |
| Botanix Sb INC | $73.38 | 2025 | Sofdra |
| Epi Health, LLC | $69.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $59.53 | 2021 | |
| Verrica Pharmaceuticals INC. | $45.35 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.93 | 2022-2023 | Spevigo |
| Biofrontera INC. | $37.89 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $33.13 | 2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $21.85 | 2022 | |
| Fidia Pharma USA INC. | $16.61 | 2025 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.